The landscape of diabetes care is undergoing a exciting shift with the emergence of rapidly melting GLP-1 medications. These novel formulations, designed to rapidly dissolve under the tongue, offer the opportunity for faster absorption and a minimized need for regular injections. This approach could improve patient adherence and potentially lead to

Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these vital therapeutic agents. The agreement enables them to handle large-scale peptide manufacturin